Tissue Repair

TB-500

Research Reagent · Laboratory Use Only

Quick Answer

What are the current research findings on TB-500 (Thymosin Beta-4) peptide?

TB-500 is a synthetic analogue of Thymosin Beta-4, a naturally occurring peptide encoded by the TMSB4X gene. Preclinical research indicates roles in actin sequestration, angiogenesis, and tissue repair signalling. Studies published in journals including Annals of the New York Academy of Sciences suggest wound-healing and anti-inflammatory properties in animal models. Human clinical data remain limited.

PMID41476424↗DOI10.1517/14712598.2010.490815↗⟳ Reconstitution Calculator
Scientific AbstractPMID 41476424 · 2026

Background

Therapeutic peptides are short-chain amino acids that regulate cellular functions and facilitate biochemical processes. In recent years, there has been significant growth in the global market for therapeutic peptides and thus its popularity among patients. Given the increase in the development of peptides and increased marketing to patients for orthopaedic injuries, it is critical for orthopaedic surgeons to understand the current evidence behind these therapeutic peptides.

Purpose

To evaluate the current evidence and applications of injectable peptide therapy, focusing on its potential in regenerative medicine and sports performance, to help orthopaedic providers better understand the current state of different therapeutic peptide approaches.

Study Design

Narrative review.

Methods

A comprehensive literature search was conducted using PubMed to identify biochemical and clinical studies on the most popular types of injectable peptide therapy. Key peptides evaluated included BPC-157, TB-4, TB-500, CJC-1295 + ipamorelin, tesamorelin, and GHK-Cu.

Results

BPC-157 demonstrated potential benefits in tendon and muscle repair, but these findings are largely unvalidated in human trials. A single human case series reported improvements in pain after intra-articular knee injections of BPC-157, although significant methodological flaws and a lack of controls limit its applicability and reliability. TB-4 and its derivative TB-500 promoted angiogenesis and tissue repair in preclinical models, but human orthopaedic data are lacking, and both remain banned substances in sports. CJC-1295 combined with ipamorelin showed significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss, but these findings are limited to animal studies. Tesamorelin, approved for treating HIV-associated lipodystrophy, has no supporting orthopaedic evidence. GHK-Cu showed promise in wound healing and anti-inflammatory effects, but no clinical data support its use for musculoskeletal conditions.

Conclusion

While peptide therapy may possess significant therapeutic and regenerative potential, it is critical that orthopaedic and sports medicine providers understand the current lack of evidence to support the clinical use of these peptides. Importantly, information regarding the indications, dosing, frequency, and duration of treatment remains unknown. Despite the popularity of these peptides in mainstream media and among patients, significant research regarding the safety and efficacy of these therapeutic methods is required before definitive recommendations can be made to patients.

Source:10.1517/14712598.2010.490815
Mechanistic Research SummaryCurated from PubMed

This data is for laboratory research purposes only. Not for human or animal consumption.

What is TB-500?

TB-500 (Thymosin Beta-4) is a synthetic peptide derivative composed of 43 amino acids that functions as a tissue repair and angiogenic agent in preclinical models. While laboratory studies demonstrate potential in wound healing and vascular regeneration, human clinical evidence remains absent, and TB-500 is classified as a banned substance in competitive sports.

Mechanism of Action

TB-500 operates through multiple pathways: it promotes angiogenesis (new blood vessel formation) by upregulating VEGF (vascular endothelial growth factor) signaling, enhances actin-binding protein interactions to facilitate cellular migration and differentiation, and modulates inflammatory response through cytokine regulation. These mechanisms theoretically support tissue repair in musculoskeletal injuries, particularly in tendon and muscle regeneration contexts, though the precise molecular cascade in human tissue remains poorly characterized.

Observed Laboratory Results

  • Preclinical angiogenesis: TB-500 demonstrated dose-dependent promotion of new capillary formation and endothelial cell migration in animal tissue repair models
  • Muscle and tendon healing: In murine models, TB-500 accelerated myogenic differentiation and collagen deposition in damaged muscle and tendon tissue
  • Absence of human orthopedic data: No randomized controlled trials, human case series with adequate controls, or clinical efficacy studies exist for musculoskeletal applications despite widespread patient marketing

Clinical Status Summary

TB-500 remains an investigational compound lacking validated human efficacy data, approved clinical indications, established dosing protocols, or defined safety profiles. Its use outside laboratory research contexts represents an evidence gap requiring substantial clinical investigation before clinical recommendation.

Clinical Research Parameters
1 trial

The following data represents formally registered clinical research studies and peer-reviewed human subject research indexed in public registries. All dose ranges, endpoints, and observations below reflect published study parameters — not recommendations. For research reference only.

Registered Clinical Trials
ClinicalTrials.gov ↗
NCT07487363 ↗
RECRUITINGPhase I / Phase IIn=80

TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD

This fictional study is an example of a ClinicalTrials.gov-style record. It describes a Phase 1/2 trial evaluating the safety and tolerability of TB-500 (a 17-23 fragment of thymosin beta 4) versus placebo in adults with stable atherosclerotic cardiovascular disease (ASCVD). Exploratory endpoints assess vascular function and inflammation biomarkers

Study Interventions
TB-500, Placebo
Primary Endpoints
incidence of treatment-emergent adverse events (TEAEs); Incidence of serious adverse events (SAEs)
Study Period
2026-02-05 → 2028-02-17
Research Compliance Notice

All data presented on this page is for laboratory research purposes only. TB-500 is referenced here as a research reagent. This page does not constitute medical advice, clinical guidance, or endorsement of any compound for human or animal use. All referenced studies are available via PubMed (PMID: 41476424) and the DOI-linked journal publication. Researchers must consult applicable institutional and regulatory frameworks before conducting any protocols.

Related Compounds

Other Tissue Repair Research Compounds

BPC-157
Body Protective Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from gastri…
→
GHK-Cu
BACKGROUND: Therapeutic peptides are short-chain amino acids that regulate cellular functi…
→
Ara-290
PURPOSE: Polymorphism and mutations of human leukocyte antigens (HLAs) and calreticulin ar…
→
AOD-9604
The analysis of low-molecular-mass peptides in doping controls has become a mandatory aspe…
→
View all Tissue Repair compounds →